文献速递烧伤创面修复

烧伤重症监护病房实施β-内酰胺类治疗药物监测服务的经验:一项回顾性病历审查

Experience with Implementing a Beta-lactam Therapeutic Drug Monitoring Service in a Burn Intensive Care Unit: A Retrospective Chart Review.
PubMed 文献 · J Burn Care Res · 2023-01-01

该回顾性病历审查纳入2016—2019年接受β-内酰胺类治疗药物监测(TDM)的烧伤成人患者,比较选择性TDM组(19例)与全员TDM组(23例)。全员TDM组更常达到目标药物浓度、启动TDM所需天数更少(p<.0001),两组临床结局相似。

要点

  • 烧伤患者中β-内酰胺类TDM可提高目标浓度达标概率并缩短启动TDM时间。
  • 全员TDM组较选择性TDM组更多进行药物浓度测量和β-内酰胺类剂量调整。
  • 两组临床治愈、培养清除、新发耐药、住院时长和死亡率等结局相似。

核心结论

  • 实施β-内酰胺类TDM方案缩短了启动TDM的时间、提高了适当目标达成的概率,并使烧伤患者的β-内酰胺类治疗个体化。

研究设计与样本

  • 回顾性病历审查,纳入2016—2019年接受β-内酰胺类TDM的烧伤成人患者,选择性TDM组19例、全员TDM组23例。
  • 纳入标准为接受头孢吡肟、哌拉西林/他唑巴坦或美罗培南≥48小时的热损伤成人患者。
  • 2016年2月至2017年7月采用基于临床判断的选择性TDM,2018年10月至2019年7月将TDM扩展至所有使用β-内酰胺类的烧伤患者。

主要发现

  • 两组最常见的原发感染部位均为皮肤和肺,最常见菌种为铜绿假单胞菌。
  • 全员TDM组患者年龄更大、危险因素更高,但更常达到目标药物浓度,启动TDM所需天数更少(p<.0001),测量和β-内酰胺类剂量调整更频繁。
  • 全部患者中临床结局良好者占77%,微生物清除者占82%。
  • 两组所有临床结局相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thermal injuries alter pharmacokinetics, complicating the prediction of standard antibiotic dose effectiveness. Therapeutic drug monitoring (TDM) has been proposed to prevent subtherapeutic dosing of antibiotic therapy, but remains scarcely studied in the burn patient population. A retrospective chart review of burn patients receiving beta-lactam TDM from 2016 to 2019 was conducted. Adult patients with thermal injury receiving cefepime, piperacillin/tazobactam, or meropenem for ≥48 hours were included. Between February 2016 and July 2017, we utilized selective TDM based on clinical judgement to guide treatment. From October 2018 until July 2019, TDM was expanded to all burn patients on beta-lactams. The primary endpoint was achievement of therapeutic concentration, and the secondary endpoints were clinical cure, culture clearance, new resistance, length of stay, and mortality. The selective (control) group included 19 patients and the universal (study) group reviewed 23 patients. In both groups, skin and lungs were the most common primary infection sources, with Pseudomonas aeruginosa as the most common species. In the universal cohort, patients were older with higher risk factors, but more frequently achieved the target drug concentration, required less days to start TDM (p < .0001), and had more frequent measurements and beta-lactam dose adjustments. Positive clinical outcome was reported in 77%, and microbial eradication in 82% of all patients. All clinical outcomes were similar between the groups. The implementation of beta-lactam TDM protocol shortened the time, increased the probability of appropriate target attainment, and individualized beta-lactam therapy in burn patients.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Alshaer M, Mazirka P, Burch G, et al. Experience with Implementing a Beta-lactam Therapeutic Drug Monitoring Service in a Burn Intensive Care Unit: A Retrospective Chart Review. J Burn Care Res. 2023. PMID: 35896122. doi:10.1093/jbcr/irac099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。